The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
Last Updated 29 September 2014 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…
Psoriatic arthritis (PsA) is an inflammatory joint disease that denotes a heterogeneous group of arthritides that may be present with or without obvious psoriatic lesions; therefore, treatment is…
Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-…
As the pharmaceutical pipeline begins to churn out specialty products at a higher rate than traditional therapies, the nation’s healthcare payers are experiencing double-digit growth in their…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Last Updated 22 May 2014 Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…